Last updated: July 27, 2026
Executive summary: Sprycel (dasatinib, BMS) remains a mature, revenue-contributing chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) therapy with multiple line-dependent indications. Clinical development activity is now dominated by label-expansion, dose-optimization, combination strategies, and life-cycle studies rather than first registrational trials. From a market and exclusivity standpoint, the competitive risk is primarily generic small-molecule entry and product lifecycle reformulations rather than biosimilar substitution (dasatinib is not biologic). Patent exposure is driven by Orange Book-listed drug substance/composition claims and method-of-use claims mapped to specific CML/Ph+ ALL regimens. Market outlook hinges on (1) ongoing net price pressure, (2) persistence/renewal dynamics versus second- and third-generation TKIs, and (3) washout to newer agents with superior tolerability profiles in frontline and subsequent-line settings.
What is Sprycel (dasatinib) approved for and how do indications map to ongoing clinical trials?
Core FDA indications (U.S.)
- CML
- Newly diagnosed Ph+ CML in chronic phase (CHR)
- Ph+ CML in accelerated phase (AP), or blast phase (BP) after prior therapy
- Ph+ CML in chronic phase after failure of prior therapy
- Ph+ ALL
- Ph+ ALL with resistance or intolerance to prior therapy
Clinical trial intent by indication
- Frontline CML: trials emphasize discontinuation strategies, fixed-dose versus response-guided approaches, and toxicity management.
- Post-TKI CML/ALL: trials focus on combination regimens, sequencing comparisons, and mechanisms of resistance (BCR-ABL kinase domain mutations, off-target signaling).
- Safety optimization: studies track pleural effusion/pulmonary hypertension risk mitigation, hematologic toxicity, and cardiometabolic comorbidities.
- MRD and response depth: trials use measurable residual disease (MRD) endpoints to support treatment de-escalation or discontinuation.
Which clinical trial types are most common for dasatinib now?
- Randomized comparisons vs other TKIs in defined mutation or toxicity strata (sequence and switching).
- Single-arm studies with time-to-event endpoints (molecular response, MRD negativity).
- Pharmacokinetic/pharmacodynamic and dose-schedule trials to manage safety.
- Combination trials pairing dasatinib with agents in resistance pathways or immune-oncology frameworks.
What is the latest clinical trials update for Sprycel (dasatinib) by phase and by endpoint?
Featured snippet answer: Recent dasatinib clinical activity is concentrated in Phase 2/3 and controlled lifecycle studies targeting response durability, MRD endpoints, and tolerability optimization, with fewer pure registrational-style studies.
Phase 2: response depth and discontinuation strategies
Typical designs include:
- MRD-guided de-escalation or stopping rules after sustained molecular response
- Comparator arms testing modified schedules or supportive prophylaxis
- Safety monitoring intensively for pleural effusion and hematologic events
Endpoints used
- Major molecular response (MMR) rate, MR4/ MR4.5 depth
- MRD negativity at time-defined checkpoints
- Progression-free survival (PFS) and overall survival (OS) where follow-up is mature
- Time to treatment failure and durability of response
Phase 3: sequencing and comparative efficacy/tolerability
Where Phase 3 studies exist, they generally test:
- Frontline versus switch timing
- Dasatinib dose or schedule differences
- Cross-trial comparisons versus imatinib or other TKIs for defined populations, including those with prior TKI exposure
Endpoints used
- Event-free survival (EFS), PFS
- Molecular response endpoints in the first 12 to 24 months
- Safety endpoints capturing discontinuation and serious adverse events
Phase 1/PK: safety management and exposure-response
Common goals:
- Lower pleural effusion burden via schedule optimization or concomitant management
- Exposure characterization in special populations (hepatic/renal impairment, elderly)
- Drug-drug interaction characterization with supportive medications used in oncology settings
How many ongoing or recently completed Sprycel clinical trials are there, and what are their themes?
Featured snippet answer: The active trial landscape for dasatinib clusters around MRD endpoints, sequencing/combination strategies, and toxicity mitigation, with many studies smaller in scale than the original registrational programs.
Trial theme map
- MRD and treatment discontinuation
- Sustained deep response as a basis for stopping or dose reduction
- Safety and tolerability
- Pleural effusion surveillance protocols and mitigation plans
- Hematologic toxicity reduction with modified schedules
- Combination therapy
- Pairing with agents targeting resistance pathways or immune response modulation
- Sequencing
- Switch logic after intolerance versus after inadequate response
- Mutation-specific
- Activity against selected BCR-ABL mutations and resistance profiles
What patents protect Sprycel (dasatinib) in the US and how strong is the patent estate?
Featured snippet answer: Sprycel’s US patent protection historically has been anchored to small-molecule composition-of-matter and dosage/formulation claims, plus method-of-use claims tied to CML/Ph+ ALL treatment regimens. The practical strength for blocking generic entry depends on which Orange Book-listed patents still list as “unexpired” for each dosage form and whether those claims cover the specific generic proposed product.
Patent estate structure (typical for dasatinib life-cycle)
- Drug substance / composition-of-matter
- Core foundational claims filed early in development
- Formulation / polymorph / particle engineering
- Claims on solid-state forms, excipients, manufacturing-related characteristics, and stability
- Method-of-use
- Regimens tied to patient subgroups, disease phases, or specific dosing strategies
Litigation relevance
- Generic risk is determined by:
- Which patents are listed in the Orange Book for dasatinib products
- Whether Paragraph IV challenges have already been resolved for each relevant patent
- Any injunctions, settlements, or consent judgments affecting launch design and timing
When does Sprycel lose exclusivity and what does that mean for generic entry timing?
Featured snippet answer: Exclusivity timing in the US for Sprycel is primarily driven by patent expiry and Orange Book status for each dosage form, with remaining life-cycle patents potentially extending protection on formulations or specific methods longer than basic composition claims.
Exclusivity mechanics relevant to Sprycel
- Patent expiration sets the primary hard stop for non-infringing generics.
- Orange Book “listed” status determines the patents a generic must address with a Paragraph IV certification to trigger potential litigation.
- Exclusivity extensions can include:
- Patent term adjustments (PTA)
- Patent term extensions (PTE) where applicable to drug approvals under relevant frameworks
- Life-cycle patenting on formulations and manufacturing
What is the Orange Book status of Sprycel (dasatinib) and which patents matter for FDA approval of generics?
Featured snippet answer: Orange Book status determines which patents a generic applicant must certify against for approval and which patents can be litigated under Paragraph IV. For a small molecule like dasatinib, the key risk is composition/formulation coverage rather than biologics exclusivity.
How to read Orange Book risk for dasatinib
- List entries per strength and dosage form
- Patent expiration dates
- Disposition history (whether challenged, settled, or expired)
- Whether claims are method-of-use versus formulation, which changes generic design space (label vs product)
Which generic companies are challenging Sprycel and what Paragraph IV outcomes affect launch dates?
Featured snippet answer: Generic entry risk for dasatinib is typically played through Paragraph IV filings targeting still-listed patents. Launch timing is affected by litigation outcomes, settlement agreements (often with “carve-outs” to avoid infringement), and FDA approval post-resolution.
Paragraph IV and settlement dynamics
- If patents are upheld or a settlement blocks launch, entry can be delayed beyond patent expiry due to:
- Design changes to avoid infringement (which may still not be sufficient)
- License terms or “authorized generic” schedules
- Consent judgments that bind the parties
What generic entry risks exist for Sprycel and how do design-around strategies typically work?
Featured snippet answer: For dasatinib generics, design-around usually focuses on avoiding active-ingredient salt/form polymorph claims, formulation composition claims, or manufacturing-process constraints tied to listed formulation patents. If method-of-use claims are asserted, label carve-outs can sometimes be used but only if the claims are not product-structure dependent.
Practical design-around vectors
- Different solid-state form or particle-size distribution if protected
- Different excipient package or manufacturing steps if formulation claims exist
- Labeling changes aligned to carve-out the claimed regimens
How does Sprycel (dasatinib) compare with other CML TKIs for commercial share and future demand?
Competitive set
- First-generation and second-generation TKIs in multiple lines (imatinib, nilotinib, bosutinib, etc.)
- Newer agents that may shift frontline preference based on safety and efficacy in defined subgroups
Decision drivers by payer and clinician
- Molecular response depth and durability
- Tolerability profile (pleural effusion and pulmonary hypertension risk for dasatinib)
- Mutation coverage and sequencing logic after resistance
- Patient comorbidity fit (cardiovascular risk, hepatic issues, need for drug interaction management)
Market analysis: how is Sprycel performing by region, line of therapy, and competitive pressure?
Featured snippet answer: Sprycel’s market is mature, and growth is limited; revenue is primarily sustained by ongoing usage in CML/Ph+ ALL and switching patterns relative to other TKIs, offset by price declines and eventual generic pressure.
Demand drivers
- Continued CML incidence and long-term treatment duration in chronic phase
- Switching from other TKIs due to intolerance or resistance
- Patient adherence influenced by side effect management and monitoring practices
Downside drivers
- Generic erosion where patents expire and Paragraph IV outcomes resolve
- Continued migration to alternative TKIs for front-line and for patients with specific risk profiles
- Payer formulary tightening and step-edits
Revenue projection: what range is most likely for Sprycel over the next 3–5 years under generic entry scenarios?
Featured snippet answer: With dasatinib now a mature branded product, the most meaningful projection swing is driven by the timing and certainty of generic entry against Orange Book-listed patents for each relevant dosage form. Where patent barriers remain, revenue typically declines gradually under price pressure; where barriers resolve, branded revenue can fall sharply post-launch.
Scenario framework for projections
- Base case: no major exclusivity loss in the next 12–24 months for the most revenue-relevant strengths, continued modest share loss to competitors, steady net price erosion.
- Upside case: delayed generic entry due to litigation/settlement or narrower list expirations; more retention of patients due to tolerability and physician familiarity.
- Downside case: earlier-than-expected generic launch across key strengths from successful Paragraph IV resolutions; high penetration in claims-covered settings accelerates revenue decline.
How does patent expiration risk differ by dosage strength and formulation for Sprycel?
Featured snippet answer: For generics, the relevant trigger is per listed dosage form and strength. If some strengths have fewer remaining listed patents, they can be approved and launched earlier, fragmenting pricing pressure across the portfolio.
Portfolio-level implications
- Separate expiration and litigation histories by strength
- Potential for staggered generic entry rather than a single portfolio-wide erosion event
- Contracting and inventory dynamics that can amplify or dampen near-term revenue hits
What manufacturing and IP barriers could slow generic or authorized generic launch of dasatinib?
Featured snippet answer: Barriers are primarily tied to formulation IP and proof burdens around bioequivalence, not biologics-style manufacturing complexity.
Where delays typically occur
- Litigation stays or design-around validation tied to formulation patents
- FDA review timing and labeling negotiations linked to carve-outs
- Supplier transition and inventory rebuilding for major wholesalers
Biosimilar risk: could a dasatinib biosimilar enter the market?
Featured snippet answer: No. Dasatinib is a small-molecule drug; replacement is via generics or authorized generics, not biosimilars.
What patent litigation affects Sprycel and how do settlements change the competitive timetable?
Featured snippet answer: Litigation outcomes and settlement agreements determine whether generics can launch at or near patent expiry, and settlements often introduce timelines that affect multiple strengths differently.
Settlement effects that matter commercially
- Delay of launch past initial expected expiry
- Narrow scope of allowed generic labeling or patient-use claims
- Agreement on payment or “reverse payment” structures where applicable (jurisdiction dependent)
- License grants that permit launch under specified conditions
Key Takeaways
- Sprycel remains an established CML/Ph+ ALL TKI with clinical development focused on MRD, sequencing, and toxicity management rather than new registrational indications.
- Patent-driven risk is the primary driver of future market erosion, with Orange Book-listed patents controlling generic certification and Paragraph IV litigation.
- Generic entry is the main competitive threat; biosimilar risk is not applicable for dasatinib.
- Revenue outlook over the next 3–5 years is most sensitive to whether remaining listed patents and litigation settlements allow staggered or portfolio-wide generic launches.
FAQs
- Which dasatinib adverse events drive treatment switching and clinical trial endpoints?
- How do BCR-ABL kinase domain mutations affect dasatinib trial eligibility and outcomes?
- What is the typical impact of generic entry on branded TKI pricing and persistence rates?
- Which CML lines of therapy show the highest sensitivity to tolerability differences between TKIs?
- What labeling carve-out patterns are used when generics attempt to avoid method-of-use infringement?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-27).
- ClinicalTrials.gov. Studies with dasatinib. (Accessed 2026-07-27).
- FDA. Sprycel (dasatinib) prescribing information. (Accessed 2026-07-27).
